Forelesere 

Andrew G. Sheard

Patent Attorney
Mr. Sheard is a leading UK Chartered Patent Attorney and a European Patent Attorney specialising in bioscience related patent matters. He set up his own specialist bioscience patent practice in 2000, following 18 years at Kilburn & Strode in London. Mr Sheard has a science degree from the University of Cambridge, and a law degree from the University of London. Over the years, he has advised a diverse clientele, including both multinational and start-up companies as well as investors, universities, government departments and research institutes.
 

Paul Fehlner

Partner at Baker Botts L.L.P.
Dr. Fehlner concentrates on intellectual property counselling in the biotechnology, chemical, pharmaceutical, medical device and material science fields. He serves clients ranging from start-up biotechnology companies to established biopharmaceutical corporations to nonprofit research institutions. He represents worldwide leaders in fully human antibodies, environmental biotechnology for waste remediation and royalty purchasing. With a Ph.D. in biochemistry and immunology and a B.Sc. in chemistry, Dr. Fehlner brings deep scientific understanding as well as legal insight to clients' problems.
 

Hans Axel Hansson

Founder of DiLab, and inventor of AccuSampler.
AccuSampler is a sampling robot that automates the sampling process for pharmacokinetics. The product helps to control and monitor the human body's reaction to, and absorption of, new drugs. AccuSampler has generated a series of different automated sampling robots with worldwide distribution. Dilab is situated in Sweden and USA. 
 

Dr. Philip M. Webber

European Patent Attorney, UK Chartered Patent Attorney
Partner, Frank B. Dehn & Co. (Oxford and London, UK)
Dr. Webber has carried out research on the regulation of brain-specific genes at Warwick University, UK, where he obtained his PhD.  As a partner in the Frank B. Dehn Life Sciences Group, he has a worldwide client-base. He is an active member of the Biotechnology Committee of the UK Chartered Institute of Patent Attorneys.  Dr. Webber has spoken at a number of European conferences and on BBC Radio on the patenting of biotech inventions, as well as publishing a number of papers in this area.
 

Øivind Enger

Analyst at Sarsia Seed. Ph.D in microbiology from Bergen University. Worked at Forinnova and Sarsia Innovation with commercialization of research-based innovations since 1999, responsible for patent strategy and use of IPR.

Roya Ghafele

Economist with the World Intellectual Property Organization. She concentrates on questions related to value creation and intellectual property in the area of life sciences. Prior to her assignment at WIPO, Roya Ghafele gained work experience with the OECD Trade Directorate, McKinsey & Company and as a professional ballet dancer. Roya Ghafele was trained at Johns Hopkins University, the Sorbonne and Vienna University. Her Ph.D. “Globalization, Francophone Africa and the WTO – a Historical Discourse Analysis” was awarded by the Austrian president with the Theodor Körner Research Prize.
 

Jens Petter Falck

Partner with Selvaag Venture Capital since 2001. Previously junior partner with Whitecliff Partners (1998-2000) and management consultant with McKinsey & Company (1994-1997).  Holds a PhD in experimental physics from MIT and a MSc in physics from the Norwegian Institute of Technology. Serves currently on the board of three portfolio companies within the areas of pharmaceuticals, offshore drilling technology and semiconductors.
 

Stein Jodal

Special advisor with Innovation Norway working with the Norwegian Government's financial support in 16 private seed capital funds. Innovation Norway's objective is to promote private and socio-economic profitable business development throughout the country, and to release the commercial opportunities of the districts and regions by encouraging innovation, internationalisation and image-building. 
  

Conny Bogentoft

Associate Professor, PhD, CEO of Karolinska Development I and II, Investment companies at Karolinska Institutet.
Vice President at Karlinska Institutet Holding AB with overall responsibility for the Karolinska Institute Innovation System. Previous positions as CEO of Karolinska Innovation AB, Vice President of Astra Arcus, President of Kabi Invent, Vice President of ACO Läkemedel. More than 30 years experience of senior R&D management in the pharmaceutical industry. Scientific Advisor to Medical Product Agency, Member of the Royal Swedish Academy of Engineering Science, Former, Chairman of the Swedish Academy of Pharmaceutical Science. At present Member of the Boards for several Biotech companies.
 

Ingwer Koch

Director and Head of Patent Law, European Patent Office (EPO)
Judge in Essen and Gelsenkirchen, Germany from 1974 to 1977. He worked at the Ministry of Justice in Bonn from 1977 to 1989. Koch has been employed at the European Patent Office, Directorate Patent Law since 1989, and as Head of the Directorate Patent Law since November 1994.
His field of duties include:
European Patent Convention including the revision project;
Law of the European Community (EC), e.g. proposal for a Directive on the patentability of computer-implemented inventions;
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) of 15 April 1994
 

Bénédicte Callan

Principle Administrator, Biotechnology Division, OECD.
Manager and senior analyst, responsible for biotechnology, innovation and health. Projects under management include: the uptake and diffusion of biotechnologies into health systems; the convergence of innovation and health policies of OECD countries; emerging research models for the delivery of health innovation.  Responsible for overseeing the Working Group on Human Health Related Biotechnologies.  Also overseeing other work in the Biotechnology Division on human health-related biotechnology (e.g. genetics and genomics).
Ms. Callan has a Ph.D. in the Fields of Comparative Politics, Asian Politics, and Methodology from University of California, Berkeley.

Jørgen Smith

Director General Norwegian Patent Office since 1992.
Master of Law (LL.M.) from University of Oslo in 1975.
Smith has extensive experience in the field of innovation policy and industrial property rights at a national, Nordic, European and international level. He participated in the UN project “New Economic World Order” in the 1970’s, in connection with the founding of the World Trade Organization (WTO) and the TRIPS Agreement, He also worked on the EEA Agreement in the 1990’s. Smith has been one of the instigators behind the establishment of the Nordic Patent Institute, which has recently been approved as an International Searching and Preliminary Examining Authority.

Thomas Grünfeld

Managing Director i Sarsia Innovation. Grünfeld er utdannet lege og har i tillegg ti års erfaring fra selskapene McKinsey og Kistefos. Sarsia Innovation er et såkornfond som jobber aktivt mot forskningsmiljøer med hovedvekt på Universitetet i Bergen. Selskapet forvalter 110 millioner kroner, og har spesialisert seg innen biovitenskap/medisin og energi.